RhumbLine Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.8M Sell
161,131
-271
-0.2% -$6.92K ﹤0.01% 1534
2025
Q4
$4.69M Sell
161,402
-21,727
-12% -$556K ﹤0.01% 1434
2025
Q3
$3.45M Sell
183,129
-2,970
-2% -$46.8K ﹤0.01% 1614
2025
Q2
$2.61M Buy
186,099
+5,025
+3% +$70.4K ﹤0.01% 1744
2025
Q1
$2.83M Buy
181,074
+13,022
+8% +$183K ﹤0.01% 1638
2024
Q4
$2.34M Buy
168,052
+4,598
+3% +$50.4K ﹤0.01% 1802
2024
Q3
$1.52M Sell
163,454
-3,835
-2% -$37.8K ﹤0.01% 2046
2024
Q2
$1.56M Buy
167,289
+41,956
+33% +$379K ﹤0.01% 2017
2024
Q1
$1.24M Buy
125,333
+18,402
+17% +$137K ﹤0.01% 2132
2023
Q4
$345K Buy
106,931
+27,501
+35% +$74.8K ﹤0.01% 2893
2023
Q3
$422K Buy
79,430
+878
+1% +$7.47K ﹤0.01% 2710
2023
Q2
$749K Buy
78,552
+24,386
+45% +$271K ﹤0.01% 2452
2023
Q1
$596K Buy
54,166
+789
+1% +$11.4K ﹤0.01% 2369
2022
Q4
$790K Buy
53,377
+8,703
+19% +$152K ﹤0.01% 2254
2022
Q3
$854K Buy
44,674
+3,329
+8% +$75.4K ﹤0.01% 2229
2022
Q2
$881K Buy
41,345
+6,005
+17% +$123K ﹤0.01% 2205
2022
Q1
$681K Sell
35,340
-262
-0.7% -$4.43K ﹤0.01% 2280
2021
Q4
$738K Buy
35,602
+18
+0.1% +$358 ﹤0.01% 2338
2021
Q3
$850K Buy
35,584
+1,300
+4% +$29.6K ﹤0.01% 2300
2021
Q2
$936K Buy
34,284
+14,151
+70% +$399K ﹤0.01% 2274
2021
Q1
$582K Buy
20,133
+45
+0.2% +$1.41K ﹤0.01% 2417
2020
Q4
$565K Buy
20,088
+3,113
+18% +$76.3K ﹤0.01% 2394
2020
Q3
$497K Buy
16,975
+5,944
+54% +$159K ﹤0.01% 2291
2020
Q2
$334K Buy
11,031
+1,150
+12% +$33.2K ﹤0.01% 2525
2020
Q1
$294K Buy
+9,881
New +$265K ﹤0.01% 2419

Other funds holding ARQT